Expression of interferon regulatory factor family and its prognostic value in acute myeloid leukemia-Reference-Cited by-同舟云学术

Expression of interferon regulatory factor family and its prognostic value in acute myeloid leukemia

Published:2023-12-06 Issue: Volume: Page:
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Zeng Jiawei¹²³⁴,Yao Jingwei²³,Zhou Yong²³,Yu Lian⁵,Zhang Li²³,Wang Caiyan²³,Luo Yiming²³,Li Zhifeng²,Xu Bing¹²³⁴^ORCID

Affiliation:

1. The School of Clinical Medicine, Fujian Medical University, Fuzhou, 351002, China

2. Department of Hematology, the First Affiliated Hospital of Xiamen University & Institute of Hematology, School of Medicine, Xiamen University, 55 Zhenhai Road, Xiamen, 361003, China

3. Key Laboratory for Diagnosis & Treatment of Hematological Malignancy of Xiamen, Xiamen, 361003, China

4. The Graduate School of Fujian Medical University, Fuzhou, 351002, China

5. Department of Hematology & Rheumatology, Longyan First Hospital, Affiliated to Fujian Medical University, Longyan, 364000, China

Abstract

Aim: To elucidate the clinicopathological and prognostic values of interferon regulatory factor ( IRF) family genes in acute myeloid leukemia (AML). Patients & methods: Differential expression analysis and survival analysis from several reliable databases were conducted and further validated using patients with AML. Results: The expression level of IRF1/2/4/5/7/8/9 in patients with AML was upregulated, while IRF3/6 expression was downregulated. High IRF1/7/9 expression indicated a worse overall survival rate. Conclusion: Overexpression of IRF1/7/9 may be associated with poor survival in patients with AML, suggesting that the IRF family may be a promising therapeutic target.

Funder

National Natural Science Foundation of China

The Natural Science Foundation of Fujian Province

Health and family planning Young Talents Project of Fujian Provincial

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2023-0443

Reference42 articles.

1. Acute myeloid leukaemia

2. Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia

3. Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy

4. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome

5. RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis